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Background. In sub-Saharan Africa, 25.5 million people are living with human immunodeficiency virus (HIV), representing 
70% of the global total. The need for second-line antiretroviral therapy (ART) is projected to increase in the next decade in keeping 
with the expansion of treatment provision. Outcome data are required to inform policy.
Methods. We performed a systematic review and meta-analysis of studies reporting the virological outcomes of protease in-
hibitor (PI)-based second-line ART in sub-Saharan Africa. The primary outcome was virological suppression (HIV-1 RNA <400 
copies/mL) after 48 and 96 weeks of treatment. The secondary outcome was the proportion of patients with PI resistance. Pooled 
aggregate data were analyzed using a DerSimonian-Laird random effects model. 
Results. By intention-to-treat analysis, virological suppression occurred in 69.3% (95% confidence interval [CI], 58.2%–79.3%) 
of patients at week 48 (4558 participants, 14 studies), and in 61.5% (95% CI, 47.2%–74.9%) at week 96 (2145 participants, 8 studies). 
Preexisting resistance to nucleos(t)ide reverse transcriptase inhibitors (NRTIs) increased the likelihood of virological suppression. 
Major protease resistance mutations occurred in a median of 17% (interquartile range, 0–25%) of the virological failure population 
and increased with duration of second-line ART.
Conclusions. One-third of patients receiving PI-based second-line ART with continued NRTI use in sub-Saharan Africa did not 
achieve virological suppression, although among viremic patients, protease resistance was infrequent. Significant challenges remain 
in implementation of viral load monitoring. Optimizing definitions and strategies for management of second-line ART failure is a 
research priority.
Prospero Registration. CRD42016048985.
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 The number of people receiving antiretroviral therapy (ART) 
in sub-Saharan Africa increased from 7.5 million in 2010 to 17 
million in 2015 [1], and expanded treatment access has led to 
substantial gains in life expectancy [2]. The Joint United Nations 
Programme on HIV/AIDS (UNAIDS) aspires to further, fast-
tracked improvements, with a target for 90% of patients knowing 
their human immunodeficiency virus (HIV) status, 90% being 
on ART, and 90% showing virological suppression by 2020 [1]. 
The World Health Organization (WHO) has advocated a public 
health approach to HIV control in sub-Saharan Africa, centered 
on standardized regimens for first-line and second-line therapy 
and, since 2015, on prompt ART initiation regardless of CD4 
cell counts [3]. Recommended first-line regimens comprise 2 
nucleos(t)ide reverse transcriptase inhibitors (NRTIs), such as 
tenofovir disoproxil fumarate (TDF) and lamivudine (3TC), 
and a nonnucleoside reverse transcriptase inhibitor (NNRTI), 
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principally efavirenz [3]. Current recommended second-line 
regimens include 2 NRTIs such as zidovudine with 3TC, and 
a boosted protease inhibitor (PI), with lopinavir/ritonavir 
(LPV/r) or atazanavir/ritonavir preferred. A  recent network 
meta-analysis has highlighted the current lack of evidence for 
alternative second-line regimens other than LPV/r with ralte-
gravir [4]. As NRTIs are continued in second-line ART, NRTI 
resistance acquired during first-line ART might represent an 
important determinant of efficacy [5, 6].
In 2013, WHO recommended adoption of plasma viral load 
(VL) monitoring to enable early identification of treatment 
failure and appropriately guide treatment changes [3]. The level 
of implementation varies across the region, and even in settings 
with access to routine VL testing, delays in switching to sec-
ond-line ART are common [7]. With further expansion in ART 
use, an increasing number of people in sub-Saharan Africa are 
at risk of treatment failure and drug resistance [8].
To inform policy related to treatment selection, monitoring, 
patient management, and access to third-line therapy, system-
atically collated data on outcomes of second-line ART, impact 
of prior NRTI resistance, and risk of emergent protease resist-
ance are needed. The aim of this study was to provide a compre-
hensive overview of data on effectiveness of second-line ART 
in sub-Saharan Africa and to present pooled estimates of viro-
logical and resistance outcomes.
METHODS
Search Strategy and Selection Criteria
PubMed, Embase, the Cochrane Register of Controlled Trials, 
Scopus, and Web of Science were searched for articles pub-
lished from 1 January 1996 to 28 July 2017 according to a pre-
defined strategy (Supplementary Table  1). References cited 
in the selected articles and abstracts from the International 
AIDS Society Conference (2014–2016) and the Conference 
on Retroviruses and Opportunistic Infections (2014–2016) 
were also reviewed. We contacted the authors of 15 studies 
to clarify definitions, obtain additional data, and remove 
duplications.
Types of Studies
We included randomized controlled trials (RCTs) and obser-
vational studies that reported the outcomes of second-line 
ART in sub-Saharan Africa with VL measured at least annu-
ally. We excluded studies with <20 participants, to avoid 
small-sample-size bias, and participants outside sub-Saharan 
Africa in international trials. We excluded studies without 
defined criteria for switching to second-line ART. For stud-
ies reporting the prevalence of drug resistance at second-line 
ART failure, we required that an unbiased selection method 
for resistance testing was applied, whereby either all patients 
meeting a defined VL threshold or a random selection were 
tested.
Types of Participants
Eligible studies investigated HIV type 1 (HIV-1)–infected par-
ticipants aged >10 years [3] who received first-line ART with 2 
NRTIs and 1 NNRTI for ≥6 months prior to switching to sec-
ond-line ART, defined as ≥2 NRTIs with a ritonavir-boosted PI. 
Clinical, immunological, or virological criteria for switching 
to second-line ART were accepted, provided the criteria were 
clearly defined.
Analyses
The intention-to-treat (ITT) analysis described outcomes for 
all patients commencing second-line ART. Participants with-
out virological data were categorized as lost to follow-up (no 
contact for ≥90  days since the last visit), died, transferred to 
another care provider, or missing data. The on-treatment ana-
lysis provided outcomes for participants who remained under 
follow-up with available VL results. For participants of obser-
vational studies who had commenced second-line ART but 
had not been in the study long enough to reach the virological 
analysis window, outcomes were imputed in proportion to the 
remaining participants in the cohort using a missing-at-ran-
dom assumption. Data prior to imputation are presented in 
Supplementary Tables 2–3.
Virological Outcomes
The primary outcome was virological suppression, defined as 
plasma HIV-1 RNA <400 copies/mL after 48 and 96 weeks of 
second-line ART, with a 24-week window period to allow for 
variations across studies (eg, measurements taken between 
weeks 36 and 60 were accepted for the 48-week outcome). The 
400 copies/mL threshold was chosen to reflect the most com-
monly used definition of virological suppression in studies from 
the region. Outcomes were further categorized as low-level vir-
emia (400–1000 copies/mL) and virological failure as per WHO 
definition (>1000 copies/mL) [3].
A secondary analysis explored how detection of NRTI resist-
ance prior to starting second-line ART influenced virological 
outcomes at week 48. We included studies with available data 
using an on-treatment analysis. The overall activity of the sec-
ond-line regimen was scored as either full or partial using the 
Stanford Resistance algorithm (version 8.2) [9].
Resistance
The prevalence of major protease resistance mutations accord-
ing to the Stanford Resistance algorithm (version 8.2) [9] after 
48 and 96 weeks was calculated as a proportion of the popula-
tion that underwent resistance testing at failure.
Data Extraction
Following the literature search and removal of duplicate cita-
tions, 2 reviewers (A. J. S., M. J. S.) independently screened the 
abstracts of retrieved records to include all potentially relevant 
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articles, and then independently reviewed the full text of the 
remaining articles. Disputes about inclusion of articles were 
resolved through discussion, with recourse to a third reviewer 
(A. M.  G.). A.  J. S.  and M.  J. S.  independently extracted data 
from the studies.
Quality Assessment
We conducted this study according to recommendations 
from the Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses (PRISMA) guidelines [10]. The quality of 
included articles was assessed using a modified version of a 
quality appraisal tool (Supplementary Materials). The review 
was registered with PROSPERO (CRD42016048985).
Statistical Analysis
Agreement between reviewers was assessed using Cohen κ 
statistic. Confidence intervals (CIs) were calculated using the 
Wilson method. Proportions were stabilized using the Freeman-
Tukey arcsine square root transformation and a pooled pro-
portion was calculated using the DerSimonian-Laird random 
effects model [11]. To assess the effect of preexisting NRTI re-
sistance on virological outcomes, we calculated the odds ratio 
(OR) of pooled rates of virological suppression at 48 weeks 
among patients receiving fully active regimens compared to 
those on partially active regimens, using a DerSimonian-Laird 
random effects model. We reported the I2 statistic, where I2 is 
interpreted as the proportion of variability in the treatment es-
timate attributable to between-study heterogeneity rather than 
sampling error. We assessed potential publication bias by visual 
inspection of funnel plots and by Egger test [12].
To determine the effect on virological outcomes of study de-
sign (randomized vs observational), median CD4 cell count, 
year of study, and duration of first-line ART, we performed 
meta-regression analysis using a restricted maximum-likelihood 
estimator mixed effects model. Analyses were conducted in Stata 
version 14.2 software (StataCorp, College Station, Texas).
RESULTS
Data Selection and Quality Assessment: Virological Outcome Studies
Following removal of duplicates, we screened 3525 abstracts 
and selected 206 full articles for review; the selection showed 
good agreement between reviewers (Cohen κ = 0.70 [95% CI, 
.63–.76]). Twenty articles describing 15 studies met the inclu-
sion criteria (Figure 1), comprising 5 RCTs [6, 13–18], 5 pro-
spective observational studies [19–25], and 5 retrospective 
observational studies [26–31]. Six studies were reported from 
multinational cohorts [13–17, 19, 23]. Data were available from 
11 of 48 (23%) sub-Saharan African countries, with study loca-
tions in western, central, eastern, and southern Africa (Figure 2 
and Table 1).
Assessment of study quality is shown in Supplementary 
Table 4. The size of the initial first-line ART population, the rate 
of first-line ART failure, and the rate of switching to second-line 
ART were poorly described. The NRTIs used in first- and sec-
ond-line regimens were inconsistently reported. The rate of 
adverse events and the contribution of tolerability to treatment 
discontinuation were not reported in most studies. In one study, 
criteria for starting second-line ART were at risk of perfor-
mance bias as they included a requirement for regular attend-
ance at clinic [20]. Sensitivity analysis excluding this trial from 
the ITT and on-treatment analyses did not significantly alter 
pooled estimates. There was no evidence of publication bias on 
inspection of funnel plots and by Egger test of asymmetry at 48 
or 96 weeks (P =  .16 and P =.19, respectively; Supplementary 
Figure 1).
Outcomes of Second-line ART
The median duration of first-line ART prior to starting 
second-line ART varied from 13 to 49  months (Table  1). 
Estimates of the rate of switching from first-line to sec-
ond-line ART were calculable for 8 studies and ranged from 
6 to 47 per 1000 patient-years. All studies used twice-daily 
LPV/r; 1 RCT randomized one-third of participants to ritona-
vir-boosted darunavir (800 mg once daily) [15]. By ITT, viro-
logical suppression rates were 69.3% (95% CI, 58.2%–79.3%) 
among 4558 participants from 14 studies at week 48, and 
61.5% (95% CI, 47.2%–74.9%) among 2145 participants from 
8 studies at week 96 (Figure  3 and Supplementary Tables 
2–3). In the on-treatment analysis, suppression rates were 
82.7% (95% CI, 76.9%–87.8%) among 3626 participants from 
15 studies at week 48, and 84.8% (95% CI, 78.8%–89.9%) 
among 1090 participants from 8 studies at week 96 (Figure 4 
and Supplementary Table  5). The rate of virological failure 
according to the WHO definition (>1000 copies/mL) ranged 
between 2.5% and 26.6% of participants at 48 weeks and 
between 4.1% and 11.1% at 96 weeks, while low-level viremia 
occurred in 0–3.3% at 48 weeks and 0–5.0% at 96 weeks, 
respectively (Supplementary Tables 2–3).
Rates of virological suppression were significantly higher 
among participants of RCTs compared to observational cohorts 
at both week 48 (85.7% [95% CI, 80.6%–90.2%] vs 58.2% [95% 
CI, 48.2%–68.0%]; P  <  .001) and week 96 (76.5% [95% CI, 
72.8%–80.4%] vs 55.7 [95% CI, 43.1%–67.8%]; P < .001). After 
exclusion of missing VL data, the difference between RCTs and 
observational cohorts persisted (P <  .0001 and P =  .001 at 48 
and 96 weeks, respectively), and estimates of virological sup-
pression rates did not significantly change (P = .39 and P = .58 
at 48 and 96 weeks, respectively). By meta-regression analysis, 
neither median CD4 cell count, nor median duration of first-
line ART at the time of starting second-line, nor the year of 
study recruitment were significantly associated with virological 
suppression, after adjustment for study design (P = .37, P = .83, 
and P = .95, respectively, at week 48; P = .91, P = .74, and P = .28, 
respectively, at week 96).
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Effect of Preexisting NRTI Resistance
Resistance test results (by conventional sequencing) were avail-
able for 6 studies [6, 14, 18, 20, 21, 23, 30]. The likelihood of 
virological suppression at week 48 was lower (OR, 0.31 [95% CI, 
.14–.70]; P = .020) among participants lacking evidence of NRTI 
resistance and therefore predicted to be receiving fully active 
second-line ART, relative to those with NRTI resistance receiv-
ing partially active second-line ART (Figure  5). Preexisting 
NRTI resistance comprised predominantly the 3TC mutation 
M184V (67.0%–92.7% of participants) and thymidine ana-
logue mutations (12.5%–74.3% of participants) (Supplementary 
Table 6).
Protease Resistance at Failure of Second-line ART
Resistance test results (by conventional sequencing) were 
available from 649 participants from 13 studies, including 5 
prospective [14, 15, 18, 23, 30] and 8 cross-sectional studies 
[32–39]. The threshold for resistance testing ranged from 400 
to 5000 copies/mL. Duration of second-line ART at the time of 
sequencing ranged from 6 to 37 months. Major protease resist-
ance mutations were present in a median of 17% (interquar-
tile range, 0–25%; range, 0–66.7%) of patients who underwent 
resistance testing (Table 2). An association between the prev-
alence of protease resistance mutations and median duration 
of second-line ART was observed (0–11.8% at 6–12 months to 
0–28.9% at 16–24 months, and 16.7%–66.7% at 27–37 months; 
r2 = 0.75, P < .001). (Figure 6).
DISCUSSION
By 2030, the number of patients requiring second-line ART in 
sub-Saharan Africa is estimated to exceed 4 million [8]. Our 
Literature search: 28 July 2017
Databases: PubMed, EMBASE, Scopus, Cochrane library, Web of Science 
Conferences: CROI 2014-2016 and International AIDS Society 2013-2015  
6120 records 
identified through 
searches   
3525 records:  
3360 articles and 165 
conference abstracts: 
title/abstract screened 
206 full text articles 
assessed for 
eligibility 
2595 duplicates 
removed 
3319 records excluded on initial screening 
178 excluded: 
   79: First-line ART outcome data 
   21: Location outside sub-Saharan Africa 
   17: Review article or editorial   
   13: Inadequate outcome data 
   11: Mathematical model 
     6: Duplicate or overlapping data  
     5: Protease inhibitor monotherapy      
     5: Non-random selection of participants 
     4: First line ART did not meet criteria 
     4: Virological or basic science study 
     4: No routine viral load monitoring      
     3: Study of resistance without routine       
             viral load monitoring      
     3: Follow up less than 48 weeks 
     1: ART naive  
     1: Resistance study: protease not sequenced 
     1: Pediatric study 
28 included articles 
describing 23 studies 
10 studies: Virologic 
outcomes of second-line 
ART only 
8 studies: Resistance at 
second-line failure 
5 studies, described by 10 
articles: Both virological 
outcomes and resistance 
Figure 1. Flow diagram of search strategy. Abbreviations: ART, antiretroviral therapy; CROI, Conference on Retroviruses and Opportunistic Infections.
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pooled ITT estimates for virological suppression after 48 and 96 
weeks of second-line ART were 69.3% and 61.5%, respectively, 
demonstrating reasonable efficacy of PI-based therapy with con-
tinued NRTI use in these treatment-experienced populations. 
Employing similar analytical methodologies, studies from India, 
China, and Cambodia reported virological suppression rates 
ranging from 70% to 85.7% over 48–96 weeks of second-line 
ART [40–42]. RCTs using LPV/r in high-income settings 
reported comparable virological suppression rates among treat-
ment-experienced patients [43]. Rates of virological suppression 
with first-line ART in low- and middle-income countries were 
similar: 67.3% and 64.6% at weeks 48 and week 96, respectively 
[44]. Thus, first- and second-line ART regimens show overall 
comparable efficacy in sub-Saharan Africa, despite the widely 
held assumption that suboptimal adherence may drive first-
line failure and continue to reduce responses after patients start 
20
50
100
200
500
Number of participants
Where studies did not describe
the distribution of patients among
multiple study sites, sample sizes
have been equally distributed across
study locations
Schramm 2014-15
Inazule 2010-15
Maiga 2012
Ndahimana 2012
Court 2009-11
Reynolds 2004-9
Levison 2009
Wallis 2008
Resistance only
Ciaffi 2010-13
Paton 2010-14
Boyd/Amin 2010-14
Boender/Sigaloff 2007-11
Johnston 2003-8
Outcomes and resistance
La Rosa 2012-13
Gross 2009-11
Schoffelen 2004-10
Osinusi-Adekanmbi 2008-11
Shearer 2004-12
Adetunji 2006-9
Wandeler 2006-12
Murphy 2006-10
Hosseinipour 2006-8
Castelnuovo 2004-6
Virologic outcomes only
Figure 2. Map of included studies.
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second-line ART. Importantly, these rates fall considerably short 
of the 90% UNAIDS target for virological suppression. Use of a 
high-genetic-barrier regimen in first-line ART (eg, with dolute-
gravir) may be required to meet these targets [45]. Although 
options for first-line ART are expanding, evidence is presently 
limited for alternative second-line options [4].
One-third of participants did not achieve virological suppres-
sion. An important reason in the ITT analysis, and a source of 
significant heterogeneity between studies, was the proportion of 
missing VL data (excluding death or loss to follow-up), which 
varied from 0 to 30%, despite accepting a 24-week window. This 
finding implies substantial challenges in implementation of VL 
monitoring. Consistent with this observation, virological out-
comes were significantly better and loss to follow-up was lower 
among RCT participants compared to those from observational 
studies, a finding that persisted after exclusion of missing VL 
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Figure 3. Forest plot of virological suppression at 48 weeks (A) and 96 weeks (B): intention–to-treat analysis, random effects model. Abbreviations: CI, confidence interval; 
VL <400, viral load <400 copies/mL.
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data. In the Europe-Africa Research Network for Evaluation of 
Second-line Therapy  (EARNEST) trial, therapy was delivered 
in a manner designed to replicate typical program settings with 
broadly generalizable entry criteria, predominantly nurse-led 
care and without real-time VL monitoring [18]. Outcomes 
were comparable to other trials with more restrictive entry 
criteria that used real-time VL monitoring. Enhanced atten-
tion to patient retention, improving staffing, and provision of 
a constant drug supply are important for ensuring improved 
treatment outcomes and are likely to account for the observed 
differences between RCTs and observational studies.
Emergence of drug resistance is common after failure of first-
line ART and is typically characterized by mutations affecting 
both NNRTIs and NRTIs [46–51]. Interestingly, detection of 
NRTI resistance and, specifically, thymidine analogue muta-
tions (TAMs) prior to starting second-line ART predicted sig-
nificantly higher odds of virological suppression [5, 14, 20, 21, 
23, 30]. An explanation is that patients who develop resistance 
Figure 4. Forest plot of virological suppression at 48 weeks (A) and 96 weeks (B): on-treatment analysis, random effects model. Abbreviations: CI, confidence interval; VL 
<400, viral load <400 copies/mL.
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at failure of first-line ART may have overall higher levels of 
adherence (and therefore greater drug selective pressure) than 
subjects who experience failure in the absence of resistance [5]. 
Importantly, the NRTIs commonly included in second-line 
regimens, such as zidovudine or TDF + 3TC, retain significant 
residual activity in the presence of TAMs and this is enhanced 
by continuation of 3TC [52, 53]. Data from the SECOND-LINE 
and EARNEST studies demonstrate that apparent paradoxical 
benefit of NRTI resistance persists at 96–144 weeks [5, 6].
Current reports of HIV epidemic control do not differentiate 
between first- and second-line ART provision, and rates of sec-
ond-line failure are not included among metrics of epidemic 
control or ART program performance [54]. Yet, between 2% 
and 26% of recipients of second-line ART experienced viro-
logical failure by 48 weeks. The optimal public health manage-
ment of second-line failure has not been adequately defined. 
In South Africa, 64% of patients experiencing viremia >400 
copies/mL (median, 3.5 log10 copies/mL) while on second-line 
ART regained virological suppression 2–4  months after tar-
geted adherence counseling [55]. This rate of resuppression 
is consistent with our finding that major protease resistance 
mutations were uncommon at virological failure, particularly 
in the first 18  months of second-line ART. Emphasis on ad-
herence is therefore necessary for second-line recipients. This 
should be differentiated from first-line failure where rapid 
emergence of NNRTI resistance is likely to limit the impact of 
adherence support. Effective adherence interventions may in-
clude weekly SMS (ie, text messaging) reminders and targeted 
counseling [56]. In cohort studies from Cambodia [57], India 
[40], and Vietnam [58], higher rates (42%–68%) of major pro-
tease mutations were observed at failure of second-line ART. 
This higher rate may reflect differences in adherence, dur-
ation of failing regimens, or an effect of viral subtypes. In our 
analysis, rates of PI resistance were strongly associated with 
increasing duration of second-line ART, suggesting that dur-
ation of PI failure is an important determinant of the need for 
third-line ART. Optimizing the frequency of VL monitoring 
and the definition of virological failure for second-line ART 
and defining appropriate regimens for third-line ART repre-
sent clear research priorities.
There are a number of limitations in our analysis. First, there 
was substantial variation in both the duration of first-line ART 
at the time of switching to second-line ART and the rate of 
switching to second-line ART among each cohort, which was 
only reported in 8 studies. The lack of consistency may represent 
a source of reporting bias. The variation in rate of switching we 
observed across studies (range, 6–47 per 1000 person years) is 
consistent with other low- and middle-income settings [7]. In 
programs with routine VL monitoring, rates of switching are 3 
times higher, suggesting potentially different outcomes in pro-
grams without monitoring [7]. Second, our analysis used aggre-
gate rather than individual patient data and, therefore, it was not 
possible to analyze the contribution of individual risk factors to 
outcomes. Third, most studies applied a VL <400 copies/mL to 
denote suppression. Data from South Africa demonstrate a con-
tinuum of risk of virological failure even with the lowest level of 
viremia (50–199 copies/mL), indicating that low-level viremia 
should trigger adherence interventions and repeat VL measure-
ment [59]. Fourth, zidovudine and stavudine, previously com-
mon components of ART regimens in sub-Saharan Africa, have 
now been replaced by TDF, and impact on NRTI resistance pro-
files and second-line ART efficacy is to be demonstrated [60].
NOTE: Weights are from random effects analysis
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In summary, reported rates of virological suppression among 
patients receiving second-line PI-based ART in sub-Saharan 
Africa are similar to those observed with first-line ART and 
comparable to the outcomes of similar regimens in Asian and 
Western settings. There is a significant gap in achieving the 
third part of the WHO 90-90-90 strategy for epidemic control. 
Reporting of second-line ART provision and rates of virolog-
ical suppression among recipients is crucial to understanding 
of epidemic control and should be strongly encouraged. Given 
that more than one-third of patients did not achieve virological 
suppression, defining the optimal definition and management 
of second-line ART failure, both with and without PI resistance, 
in this setting is an urgent research priority.
Supplementary Data
Supplementary materials are available at Clinical Infectious Diseases online. 
Consisting of data provided by the authors to benefit the reader, the posted 
materials are not copyedited and are the sole responsibility of the authors, 
so questions or comments should be addressed to the corresponding author.
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Figure 6. Proportion of participants with major protease mutations according to duration of second-line antiretroviral therapy at virological failure. Areas of circles are 
proportional to size of cohort failing second-line treatment. Solid line and dashed line are quadratic line of best fit and 95% confidence interval, respectively. Major protease 
resistance mutations according to the Stanford HIV resistance database version 8.2 [9]. Abbreviations: ART, antiretroviral therapy; PI, protease inhibitor.
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